Pharmaceutical CDMO Manufacturers and Market Growth
The global pharmaceutical CDMO market size was estimated at US$ 146.05 billion in 2023 and is projected to grow to US$ 315.08 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.24% from 2024 to 2034.
Top Companies in the Pharmaceutical CDMO:
- Veranova
- Sterling
- Fareva
- Pfizer Centre One
- AjiBio
- Uquifa
- Farmhispania
- Carbogen Amcis
- Evonik
- FIS - Fabbrica Italiana Sintetici S.p.A.
- Almac
- Dottikon
- Curia
- CordenPharma International
- Piramal Pharma Solutions
- Samsung Biologics
- WuXi AppTec, Inc.
- Siegfried Holding AG
- Cambrex Corporation
- Bushu Pharmaceuticals Ltd.
- EuroAPI
- Laboratory Corporation of America Holdings (LabCorp)
- Sequens
- Hovione
- Nipro Corporation
- Catalent, Inc.
- Thermo Fisher Scientific, Inc.
- Recipharm AB
- Axplora
- Lonza
Recent Announcements by Industry Leaders
In October 2023, the whole pharmaceutical supply chain and more than 40,000 executives are expected to attend CPHI Barcelona, which will be held at Fira Barcelona from October 24 to 26. In addition to being a top business show, this event, which is essential to the pharmaceutical industry, has developed into a crucial forum for conversations on outsourcing and the pharmaceutical and biotech sectors.
Recent Developments in the Pharmaceutical CDMO Market
- In October 2023, the CDMO Intelligence solution from Norstella firm Evaluate was launched today. In order to make well-informed judgments and maximize long-term strategies in the intricate and quickly growing pharmaceutical CDMO industry, it will give contract development and manufacturing organizations (CDMOs), biopharma businesses, and finance institutions thorough and objective market knowledge.
- In September 2023, the CDMO service was just launched by Future Fields, a biotechnology business that developed the first synthetic biology system in the world to employ fruit flies for the creation of recombinant proteins.
If you have any questions, please feel free to contact us at
